Pulmonary Cell News 7.44 November 8, 2018 | |
| |
TOP STORYTo test whether loss of glutathione (GSH)/GSH reductase (GSR) sensitizes cancer cells to thioredoxin/thioredoxin reductase (TXNRD) inhibition, investigators knocked out or knocked down the GSR gene in human lung cancer cells and evaluated their response to the TXNRD inhibitor auranofin. [Cancer Res] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Fas Activation Alters Tight Junction Proteins in Acute Lung Injury Activation of the Fas pathway increased protein permeability in mouse lungs and altered the expression of the tight junction proteins occludin and zonula occludens-1 in the alveolar-capillary membrane in vivo and in human alveolar epithelial cell monolayers in vitro. [Thorax] Abstract Scientists found that miR-29b was dynamically down-regulated by silica and influenced the promotion of mesenchymal-epithelial transition in RLE-6TN cells. Furthermore, delivery of miR-29b to mice significantly inhibited silica-induced epithelial-mesenchymal transition, prevented lung fibrosis and improved lung function. [Mol Ther Nucleic Acids] Abstract | Full Article | Graphical Abstract Researchers identified E2F1-responsive genes, including Nmyc, as targets repressed by additional sex combs-like 1 (ASXL1). Together with E2F1 and ASXL1, host cell factor 1, purified as an Asxl1-bound protein, was recruited to the E2F1-binding site of the Nmyc promoter. [Cell Death Dis] Full Article PIWI Proteins Contribute to Apoptosis during the UPR in Human Airway Epithelial Cells The authors demonstrated that endoplasmic reticulum stress specifically up-regulated total piwi-interacting RNA expression profiles, and these changes correlated with unfolded protein response (UPR)-induced apoptosis as shown by up-regulation of two pro-apoptotic factor mRNAs, CHOP and NOXA. [Sci Rep] Full Article Investigators showed that PU.1, the myeloid transcription factor, co-operated with the vitamin D receptor and CCAAT/enhancer binding protein α (CEBPα) to enhance the induction of cathelicidin antimicrobial peptide in lung epithelial cells. [J Cell Physiol] Abstract LUNG CANCERmiR-411-5p/3p overexpression could accelerate cell proliferation and migration, and impede cell apoptosis in non-small cell lung cancer cell lines. In addition, scientists showed that miR-411-5p also targeted tumor suppressor TXNIP, involved in regulating positively cell cycle progress in SPC-A1 cells rather than in H1299. [Oncogene] Full Article Overexpression of tubulin polymerization promoting protein family member 3 (TPPP3) remarkably promoted non-small-cell lung carcinoma cell migration and invasion along with the upregulation of Twist1 both in vitro and in vivo. Further investigations showed that activation of STAT3 was required for TPPP3-mediated upregulation of Twist1, cell migration and invasion. [Cell Physiol Biochem] Full Article ZNF326 Promotes Proliferation of Non-Small Cell Lung Cancer Cells by Regulating ERCC1 Expression Investigators showed that ZNF326 significantly promoted cell cycle progression, colony formation, and proliferation as well as the growth of non-small cell lung cancer transplanted tumors. They confirmed that the C2H2 structure of ZNF326 binds to the −833 to −875 bp region of the ERCC1 promoter to initiate transcriptional activity. This binding promoted CyclinB1 synthesis and cell cycle progression. [Lab Invest] Abstract Thymoquinone-Induced Antitumor and Apoptosis in Human Lung Adenocarcinoma Cells Thymoquinone (TQ) decreased the viability and increased apoptotic cell death in A549 human lung tumor cells. TQ treatment significantly elevated the Bax/Bcl-2 ratio in the lung cancer cells. TQ also upregulated p53 expression, another apoptotic modulator in A549 cancer cells. [J Cell Physiol] Abstract Subscribe to one of our other 19 science newsletters such as Cancer Stem Cell News & Human Immunology News. | |
| |
REVIEWSThe authors provide a detailed overview of possible underlying factors that link COPD and lung cancer, and current therapeutic advances from both human and preclinical animal models that can effectively mitigate this unholy relationship. [Drugs] Abstract Aquaporins (AQP) facilitate water flux across cell membranes, and as such, they provide a transcellular route for water transport across epithelia. However, their contribution to near-isosmolar fluid conditions in the lung still remains elusive. Investigators discuss the role of AQPs in the lung with regard to fluid homeostasis across the respiratory epithelium. [Pflugers Arch] Full Article Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
SCIENCE NEWSBerGenBio ASA announced that a late-breaking abstract detailing median progression-free-survival during the first stage of its Phase II clinical trial with bemcentinib, in combination with the anti-PD-1 therapy KEYTRUDA® in patients with previously treated, advanced non-small cell lung cancer (NSCLC) has been published and will be presented. [Press release from BerGenBio ASA discussing research to be presented at the Annual Society for Immunotherapy in Cancer (SITC) 2018 Congress, Washington D.C] Press Release Mirati to Present New Data in Ongoing Phase II Clinical Trials Preliminary biomarker data from the ongoing Phase II clinical trial of sitravatinib in combination with nivolumab in non-small cell cancer lung (NSCLC) patients will be presented along with a data update in the ongoing Phase II clinical trial of mocetinostat in combination with durvalumab in NSCLC patients. [Press release from Mirati Therapeutics, Inc. discussing research to be presented at the Annual Society for Immunotherapy in Cancer (SITC) 2018 Congress, Washington D.C] Press Release | |
| |
INDUSTRY NEWSImmunomedics, Inc. announced its current clinical collaboration with AstraZeneca and MedImmune for the development of Imfinzi® and sacituzumab govitecan combination therapy has been broadened to include second-line metastatic non-small cell lung cancer. [Immunomedics, Inc.] Press Release U.S. FDA Approves LORBRENA® (Lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC Pfizer Inc. announced that the FDA has approved LORBRENA®, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease. [Pfizer Inc.] Press Release Gala Therapeutics announced that the first two patients in the early feasibility study of RheOx™ for chronic bronchitis were treated at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania. [Gala Therapeutics Inc.] Press Release Spero Therapeutics, Inc. announced results from preclinical IND-enabling studies of SPR720, an oral antimicrobial agent being developed for the treatment of pulmonary non-tuberculous mycobacterial infections. [Spero Therapeutics] Press Release Exploring Autophagy in the Development of Non-Small Cell Lung Cancer Rutgers Cancer Institute of New Jersey researcher ‘Jessie’ Yanxiang Guo, PhD, has received a $150,000 grant from the Lung Cancer Research Foundation to investigate the role of a cell survival mechanism known as autophagy in the development of lung cancers driven by mutations in tumor suppressors known as LKB1 and oncogene KRAS. [Rutgers, The State University of New Jersey] Press Release This year, the Bonnie J. Addario Lung Cancer Foundation-Van Auken Private Foundation awarded $500,000 to two teams of innovative researchers; one developing technology to improve early lung cancer detection and the other creating probiotics to treat lung cancer. [The Bonnie J. Addario Lung Cancer Foundation] Press Release Flutiform® Receives a Positive Opinion in Europe for the Treatment of Children with Asthma The Mundipharma network of independent associated companies announced that the European Decentralised Procedure licence variation application for flutiform®, extending the indication to the treatment of asthmatic children, has closed with a positive opinion. [Mundipharma International] Press Release | |
| |
POLICY NEWSScientists Struggle with Confusing Journal Guidelines Globally, more than two-thirds of researchers find it difficult to prepare manuscripts and to respond to peer-review comments, finds a survey of nearly 7,000 researchers from over 100 countries. [Nature News] Editorial Open-Access Plan Draws Online Protest Hundreds of scientists are pushing back against Plan S, a plan to crack down on scholarly journals’ paywalls, launched 2 months ago by 11 national research funders in Europe. In an open letter published on 5 November, about 800 signatories say they support open access—making papers available free to all readers online—but condemn Plan S as “too risky for science.” [ScienceInsider] Editorial
| |
EVENTSNEW Gordon Research Conference: Stem Cells and Cancer Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESAssociate Professor – Oncology (University of California, Davis) Postdoctoral Scholar – Cancer Metabolism (The Moffitt Cancer Center) Chair – Cancer Metabolomics Non-Clinical (Imperial College of London) Postdoctoral Position – Lung Cancer Biology (UT Southwestern Medical Center) Postdoctoral Research Scientist – Modeling Infection in Human Lung Organoids (Columbia University) Postdoctoral Position – Human Lung Organoid Research (Columbia University Medical Center) Postdoctoral Fellow – Vascular and/or Lung Biology (Yale University) Postdoctoral Fellow – Sepsis and Pulmonary Injury Research (University of Maryland) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|